Table 1.
Control | Sepsis | |
N | 53 | 53 |
PRMT4, mean (SD, ng/mL) | 7.8 (11.0) | 18.4 (28.6) |
Demographics | ||
Age (years), mean (SD) | 55 (15.0) | 55 (17.5) |
Male, n (%) | 31 (58.5) | 24 (45.3) |
BMI, mean (SD) | 28.8 (9.1) | 30.9 (9.4) |
Comorbidities, n (%) | ||
Diabetes | 16 (30.2) | 22 (41.5) |
COPD | 6 (11.3) | 11 (20.7) |
Immunosuppression | 9 (17) | 9 (17) |
Chronic cardiac failure | 3 (5.7) | 7 (13.2) |
Chronic kidney disease | 6 (11.3) | 5 (9.4) |
Pulmonary fibrosis | 0 (0) | 2 (3.8) |
Active neoplasm | 3 (5.7) | 3 (5.7) |
Chronic liver disease | 9 (17) | 6 (11.3) |
Alcohol use | 13 (24.5) | 8 (15.1) |
Severity of Illness | ||
SOFA score,1 mean (SD) | 5.2 (2.4) | 7.4 (2.6) |
PaO2:FiO2 ratio, mean (SD) | 224 (152) | 196 (88) |
Shock, n (%) | 10 (18.9) | 34 (64.2) |
Acute kidney injury, n (%) | 22 (41.5) | 40 (75.5) |
ICU LOS (days), mean (SD) | 8.5 (9.4) | 13.4 (9.8) |
30-day mortality, n (%) | 6 (11.3) | 12 (22.6) |
90-day mortality, n (%) | 7 (13.2) | 13 (24.5) |
BMI, body mass index; FiO2, fraction of inspired oxygen; ICU, intensive care unit; LOS, length of stay; PaO2, arterial partial pressure of oxygen; PRMT4, protein Aarginine N-methyltransferase 4; SOFA, sequential organ failure assessment.